Format

Send to

Choose Destination
Liver Cancer. 2014 Oct;3(3-4):458-68. doi: 10.1159/000343875.

JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan.

Author information

1
Department of Gastroenterology and Hepatology, Kinki University School of Medicine, Osaka, Japan.
2
Department of Radiology, Kanazawa University Graduate School of Medical Science, Ishikawa, Japan.
3
Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan.
4
Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan.
5
Department of Radiology, Shinshu University School of Medicine, Nagano, Japan.
6
Department of Gastroenterology, Ikeda Municipal Hospital, Osaka, Japan.
7
Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan.
8
Department of Diagnostic Radiology, Fukuiken Saiseikai Hospital, Fukui, Japan.
9
Department of Gastroenterology, Ehime Prefectural Central Hospital, Ehime, Japan.
10
Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Chiba, Japan.
11
Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, Chiba, Japan.
12
Department of Gastroenterology, Kanazawa University Hospital, Ishikawa, Japan.
13
Department of Radiology, Kanazawa University Hospital, Ishikawa, Japan.
14
Department of Interventional Radiology, Mie University School of Medicine, Mie, Japan.

Abstract

The Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma proposed by the Japan Society of Hepatology was updated in June 2014 at a consensus meeting of the Liver Cancer Study Group of Japan. Three important items have been updated: the surveillance and diagnostic algorithm, the treatment algorithm, and the definition of transarterial chemoembolization (TACE) failure/refractoriness. The most important update to the diagnostic algorithm is the inclusion of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging as a first line surveillance/diagnostic tool. Another significant update concerns removal of the term "lipiodol" from the definition of TACE failure/refractoriness.

KEYWORDS:

Clinical practice guidelines; Definition of transarterial chemoembolization failure; Hepatocellular carcinoma; Japan Society of Hepatology; Liver Cancer Study Group of Japan

Supplemental Content

Full text links

Icon for S. Karger AG, Basel, Switzerland Icon for PubMed Central
Loading ...
Support Center